The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for RAPT Therapeutics Inc. (RAPT) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.34, or -1.28%, to $26.25. The RAPT Therapeutics Inc. has recorded 19,570 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.
RAPT Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $26.59 and fluctuated between $26.62 as its day high and $24.27 as its day low. The current market capitalization of RAPT Therapeutics Inc. is $899.54M. A total of 0.66 million shares were traded on the day, compared to an average of 370.53K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, RAPT has seen 0 BUY and 3 SELL insider trades, representing the acquisition of 0 and the disposition of 12,000 shares. Over the last 12 months, there were 38 BUYs and 12 SELLs from insiders. Insiders purchased 2,584,108 shares during that period but sold 34,162.
In the most recent transaction, Brockstedt Dirk G. sold 742 shares of RAPT for 21.97 per share on Jan 05. After the transaction, the Chief Scientific Officer now owns 19,070 company shares. In a previous transaction on Dec 29, HO WILLIAM sold 5,000 shares at 18.03 per share. RAPT shares that Chief Medical Officer owns now total 37,650.
Among the insiders who sold shares, HO WILLIAM disposed of 5,000 shares on Nov 28 at a per-share price of $17.87. This resulted in the Chief Medical Officer holding 42,650 shares of RAPT after the transaction. In another insider transaction, HO WILLIAM sold 5,000 shares at $22.32 per share on Nov 02. Company shares held by the Chief Medical Officer now total 47,650.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for RAPT in the last 3 months, the mean price target is $46.20 with high estimates of $61.00 and low estimates of $27.00. In terms of 52-week highs and lows, RAPT has a high of $33.96 and a low of $9.85.
As of this writing, RAPT has an earnings estimate of -$0.67 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.47 per share and a lower estimate of -$0.78. The company reported an EPS of -$0.69 in the last quarter, which was -1.50% lower than expectations of -$0.68.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RAPT is Hold with a score of 5.00. A total of 9 analysts rated the stock as Buy while 1 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.